Lin I-Hung, Kuo Bo-I, Liu Fang-Yu
Department of Ophthalmology, Tri-Service General Hospital, National Defense Medical Center, Taipei City 11490, Taiwan.
Department of Ophthalmology, Taipei City Hospital Renai Branch, Taipei City 10629, Taiwan.
Medicina (Kaunas). 2021 Apr 22;57(5):404. doi: 10.3390/medicina57050404.
The efficacy of combined intravitreal bevacizumab injection with systemic chemotherapy, palliative radiotherapy, and hormonal therapy to treat choroidal and orbital metastases is not known. Herein, we report the case of a 48-year-old woman with systemic chemotherapy-resistant choroidal and orbital metastases of the left eye originating from a stage IV invasive ductal carcinoma of the left breast. We describe the addition of a single intravitreal injection of bevacizumab in addition to treatment with systemic chemotherapy, hormonal therapy, and palliative radiotherapy. The patient's outcome at 6-month follow-up was favorable, as the metastatic lesion reduced in size and visual acuity improved. Combined treatment with intravitreal bevacizumab injection, systemic chemotherapy, palliative radiotherapy, and hormonal therapy can resolve ocular metastatic lesions originating from breast cancers.
玻璃体内注射贝伐单抗联合全身化疗、姑息性放疗及激素治疗对脉络膜和眼眶转移瘤的疗效尚不清楚。在此,我们报告一例48岁女性患者,其左眼脉络膜和眼眶转移瘤对全身化疗耐药,原发于左乳IV期浸润性导管癌。我们描述了在全身化疗、激素治疗和姑息性放疗的基础上,额外单次玻璃体内注射贝伐单抗的情况。患者在6个月随访时预后良好,转移病灶缩小,视力改善。玻璃体内注射贝伐单抗联合全身化疗、姑息性放疗及激素治疗可消除源自乳腺癌的眼部转移病灶。